![]() Needham slightly increased the price target for Blueprint Medicines Corp (NASDAQ:BPMC) from $65 to $66 with a Buy rating. Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions Blueprint Medicines lead drug Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, was approved by the Food and Drug Administration (FDA) to treat PDGFRA Exon 18 mutant gastrointestinal. Image source: SEC official website What is a statement of changes in shareholding? The SEC requires insiders of listed companies to publicly disclose their securities transactions and According to 16 analysts, the average rating for BPMC stock is 'Buy.' The 12-month stock price forecast is 79. In the short term (2weeks), BPMCs stock price should underperform the market by -0.29.During that period the price should oscillate between -7.55 and +7.87. The average Blueprint Medicines stock price. 19, 2022 when the stock price was at 69.66. On average, Wall Street analysts predict that Blueprint Mediciness share price could reach 70.80 by Aug 21, 2024. ![]() For details of the disclosing party's derivatives transactions, please refer to the form. Market cap is calculated by taking a companys price per share and multiplying it by the companys total number of shares outstanding. BPMC stock forecast Our latest prediction for Blueprint Medicines Corps stock price was made on the Aug. ![]() sold 25,000 common shares at an average price of 49.81 US dollars per share on August 24 and 25, worth about 1,245,200 US dollars. On August 29, it was reported that according to documents disclosed by the US Securities and Exchange Commission (SEC) on August 28, $Blueprint Exchanges (BPMC.US) $ director Albers Jeffrey W. Following the Form 4 filing with the SEC, Albers has control over a total of 176,050 sīlueprint Investments (BPMC.US) directors sold 25,000 common shares worth approximately $1,245,200 and Analysts Give Mixed Ratings Best Stocks about 7 hours ago Blueprint Medicines (NASDAQ:BPMC) Shares Down 3. ![]() Albers, Director, on August 24, 2023, sold 25,000 shares in Blueprint Medicines (BPMC) for $1,245,150. Wellington Management Group LLP Increases Holdings in Blueprint Medicines Co. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |